Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;26(3):682-688.
doi: 10.1007/s12094-023-03288-1. Epub 2023 Aug 4.

Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution

Marta Sotelo #  1 , Nerea Muñoz-Unceta #  1 , Antonio Matorras  2 , Pablo Jara  1 , Clara Castro  1 , Diego Cacho  1 , Belén Caramelo  1 , Ainara Azueta  3 , Ignacio Durán  4   5
Affiliations
Review

Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution

Marta Sotelo et al. Clin Transl Oncol. 2024 Mar.

Abstract

Purpose: Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment of metastatic urothelial carcinoma (mUC) upon platinum-based chemotherapy according to the positive results of large clinical trials. Nevertheless, results from unselected populations reflecting real-world data (RWD) are highly informative to the clinician. We reviewed daily clinical practice outcomes in patients with mUC who received atezolizumab in our institution.

Methods: Here we evaluated the clinical activity and safety of atezolizumab in an unselected population of mUC patients who received atezolizumab between 2018 and 2022 reflecting RWD. Efficacy and safety information were retrospectively collected.

Results: A total of 63 patients were included. The mean age was 68 years and the objective response rate was 14.3%. The median progression-free survival was 3 months and the median overall survival 6 months. At 1 year, 42% of the patients were alive. ECOG (0 vs 1) and neutrophil-lymphocytes ratio < 2 at the start of ICI were positive prognostic factors that discriminated between long vs short survivors. Overall tolerance was good with no new safety signals. Five patients (17%) had treatment-related adverse events grade ≥ 2 that required corticosteroids.

Conclusion: In this retrospective study, atezolizumab was an effective and tolerable treatment option for patients with mUC after progression to platinum-based chemotherapy. Yet, patient selection remains critical to improve outcomes.

Keywords: Atezolizumab; Bladder cancer; Immune checkpoint inhibitors; Real-world data.

PubMed Disclaimer

References

    1. WHO Cancer Mortality Databse. In: https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf . Accesed 26 Feb 2023
    1. Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Ljunberg B, et al. The 2022 updated European association of urology guidelines on the use of adjuvant immune checkpoint inhibitor therapy for renal cell carcinoma. Eur Urol. 2023;83(1):10–4. https://doi.org/10.1016/j.eururo.2022.10.010 . - DOI - PubMed
    1. Valderrama BP, González-Del-Alba A, Morales-Barrera R, Peláez Fernández I, Vázquez S, Caballero Díaz C, et al. SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021). Clin Transl Oncol. 2022;24(4):613–24. https://doi.org/10.1007/s12094-022-02815-w . - DOI - PubMed - PMC
    1. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737–45. https://doi.org/10.1001/jama.2011.1142 . - DOI - PubMed - PMC
    1. Liu S, Yang T, Na R, Hu M, Zhang FuY, et al. The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27912 patients. Int Urol Nephrol. 2015;47(6):951–8. https://doi.org/10.1007/s11255-015-0980-6 . - DOI - PubMed

LinkOut - more resources